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ABSTRACT 
Aims: B56α is a protein phosphatase 2A (PP2A) regulatory subunit that is highly expressed 
in the heart. We previously reported that cardiomyocyte B56α localises to myofilaments 
under resting conditions and translocates to the cytosol in response to acute β-adrenergic 
receptor (β-AR) stimulation. Given the importance of reversible protein phosphorylation in 
modulating cardiac function during sympathetic stimulation, we hypothesised that loss of 
B56α in mice with targeted disruption of the gene encoding B56α (Ppp2r5a) would impact 
on cardiac responses to β-AR stimulation in vivo. Methods and results: Cardiac phenotype 
of mice heterozygous (HET) or homozygous (HOM) for the disrupted Ppp2r5a allele and 
wildtype (WT) littermates was characterised under basal conditions and following acute β-
AR stimulation with dobutamine (DOB; 0.75 mg/kg i.p.) or sustained β-AR stimulation by 2-
week infusion of isoproterenol (ISO; 30 mg/kg/day s.c.). Left ventricular (LV) wall 
thicknesses, chamber dimensions and function were assessed by echocardiography, and heart 
tissue collected for gravimetric, histological and biochemical analyses. Western blot analysis 
revealed partial and complete loss of B56α protein in hearts from HET and HOM mice, 
respectively, and no changes in the expression of other PP2A regulatory, catalytic or 
scaffolding subunits. PP2A catalytic activity was reduced in hearts of both HET and HOM 
mice. There were no differences in the basal cardiac phenotype between genotypes. Acute 
DOB stimulation induced the expected inotropic response in WT and HET mice, which was 
attenuated in HOM mice. By contrast, DOB-induced increases in heart rate were unaffected 
by B56α deficiency. In WT mice, ISO infusion increased LV wall thicknesses, 
cardiomyocyte area and ventricular mass, without LV dilation, systolic dysfunction, collagen 
deposition or foetal gene expression. The hypertrophic response to ISO was blunted in mice 
deficient for B56α. Conclusions: These findings identify B56α as a potential regulator of 
cardiac structure and function during β-AR stimulation.  
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INTRODUCTION 
Phosphorylation is a post-translational modification that plays a fundamental role in 
modulating cardiac structural and functional responses to neurohormonal stimuli. Activation 
of cardiac β-adrenergic receptors (β-ARs) leads to the dynamic phosphorylation and 
dephosphorylation of myofilament proteins (e.g. cardiac troponin I (cTnI), cardiac myosin 
binding protein C (cMyBP-C)1-3) and calcium handling proteins (e.g. ryanodine receptor 2 
(RyR2), phospholamban (PLB), L-type Ca2+ channel4), as well as transcriptional regulators 
(e.g. transcription factors,5 histone deacetylases6, 7). Much research effort to date has focussed 
on identifying the kinase signalling pathways that facilitate the phosphorylation of 
functionally important cardiac proteins downstream of physiologically relevant stimuli (see 
Solaro8 for review). However, there is increasing recognition of the importance of 
dephosphorylation by protein phosphatases in regulating cardiac homeostasis and 
contractility of the healthy and diseased heart.9 Indeed, protein phosphatase expression and 
activity is dysregulated in the failing heart,9 and abnormal phosphorylation of several cardiac 
proteins that are phospho-regulated in response to β-AR stimulation has been causally 
associated with various forms of cardiomyopathy.10, 11 
The type 1 and type 2A protein phosphatases (PP1 and PP2A, respectively) provide the 
majority of serine/threonine phosphatase activity in the myocardium, and play critical roles in 
the regulation of cardiac function.9, 12, 13 PP2A is a heterotrimeric enzyme consisting of a 
catalytic C subunit (PP2AC, encoded by PPP2CA and PPP2CB), a scaffolding A subunit 
(PP2AA, encoded by PPP2R1A and PPP2R1B) and a regulatory B subunit (encoded by at 
least 15 different genes, including members of the PPP2R2, PPP2R3, PPP2R5 and STRN 
families, with multiple splice variants). The diversity of PP2A cellular functions derives from 
the fact that numerous biochemically distinct complexes may be assembled from different 
combinations of A, B and C subunits, with the regulatory B subunits providing the essential 
determinants for subcellular targeting, substrate specificity and fine-tuning of phosphatase 
activity.14, 15  
B56α is a member of the B56 or B’ family of PP2A regulatory subunits, and is most abundant 
in the heart and skeletal muscle.16 We identified B56α as a potential regulator of cardiac β-
adrenergic signalling from a proteomic screen in which ventricular myocytes from adult rat 
hearts were treated with isoproterenol (ISO) to activate β-AR signalling, and then ‘skinned’ 
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to disrupt sarcolemmal membranes and deplete cytosolic proteins.17 B56α was found to 
associate with the Z disc and M-band of sarcomeres in resting cardiomyocytes, and to 
translocate from the myofilaments to the cytosol in response to acute β-AR stimulation.17 We 
have recently reconfirmed B56α translocation in response to β-AR stimulation in adult rat 
ventricular myocytes and found that another B56 isoform, B56d, displays increased 
phosphorylation (at a unique Ser573 residue) but no translocation following β-AR 
stimulation in that cell type.18 In other pertinent studies, transgenic overexpression of B56α in 
the murine heart was associated with reduced phosphorylation of myofilament proteins, 
including cTnI, cMyBP-C, cardiac troponin T, and myosin light chain 2,19 and B56α 
expression in left ventricular tissue was found to be dramatically reduced in failing human 
myocardium.20 Together, these findings suggest that changes in the abundance or subcellular 
distribution of B56α may be of functional significance in physiological and 
pathophysiological settings.  
Here, we investigate how loss of B56α impacts on cardiac responses to β-AR activation in 
vivo, using a genetically modified mouse model with targeted disruption of the gene encoding 
B56α (Ppp2r5a). We report that loss of B56α attenuates the inotropic response to acute β-AR 
stimulation and blunts left ventricular (LV) hypertrophy in response to sustained β-AR 
stimulation. Our findings reveal a potential new role for B56α in the regulation of cardiac 
structural and functional responses to β-AR activation in vivo.  
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METHODS 
Experimental animals 
Mice with targeted disruption of Ppp2r5a via gene-trap insertion of a BGEO cassette in 
intron 1 were generated at Texas A&M Institute for Genomic Medicine (Texas, USA) and 
maintained on a C57BL/6 background at St Thomas’ Hospital (London, UK). Mice 
heterozygous (HET) or homozygous (HOM) for the mutant allele and wildtype (WT) 
littermates were genotyped by PCR using forward primers (5’-
CTTGCAAAATGGCGTTACTTAAGC-3’, 5’-CATCTGGTTAGTCTTGAGATGC-3’) and 
a reverse primer (5’-TATCAAGGGCACTGCCAAAG-3’) to amplify 370 and 290 bp 
regions of the WT and mutant alleles, respectively. Male and female mice from all three 
genotypes and different ages (2 months, 6 months) were included in this study. No signs of 
infertility, premature mortality or developmental defects were observed. Animal experiments 
were conducted in accordance with the Home Office Guidance on the Operation of Animals 
(Scientific Procedures) Act 1986, published by Her Majesty’s Stationary Office, London.  
Dobutamine administration  
Dobutamine-stress-echocardiography was performed on male WT, HET and HOM mice as 
described previously.21 In brief, mice were randomly assigned to receive a single bolus 
intraperitoneal injection of dobutamine (DOB; 0.75 mg/kg) or an identical volume of vehicle 
(0.9% NaCl). Echocardiographic and ECG recordings obtained 10 min after DOB/vehicle 
administration were analysed. 
Isoproterenol infusion 
WT and HOM mice received a continuous infusion of isoproterenol (ISO; 30 mg/kg/day) or 
vehicle (0.9% NaCl) for 14 days via subcutaneously-implanted osmotic minipumps (ALZET 
model 1002; supplied by Charles River UK Ltd, Kent, UK), as described previously.21 
Echocardiographic recordings were obtained prior to minipump implantation and at the end 
of the infusion period, and hearts were collected for gravimetric, histological and biochemical 
analyses. ISO (DL-Isoproterenol hydrochloride) was from Sigma (MO, USA).  
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Echocardiography 
Echocardiography was performed on anaesthetized mice (1.5-2% isofluorane) using the 
VisualSonicsVevo® 770 imaging system (Scanhead: RMV707B, 15-45 MHz, cardiac 
mouse), as described previously.21 End-systolic and end-diastolic measurements of 
interventricular septum (IVS) thickness, left ventricular internal dimension (LVID) and left 
ventricular posterior wall (LVPW) thickness were obtained from parasternal long-axis 
projections, and left ventricular anterior wall (LVAW) thickness was obtained from short-
axis projections. Measurements of LV dimensions were obtained from three beats and 
averaged. LV fractional shortening (FS) [(LVID;d – LVID;s)/LVID;d*100%] and LV 
ejection fraction (EF) [(LVvol;d – LVvol;s)/LVvol;d]*100% were calculated from M-mode 
measurements. ECG and respiration gating were used to suppress movement artefacts. 
Tissue sampling and processing 
Mice were anaesthetised with 4% isoflurane and killed by cervical dislocation. Tissue 
collection and processing was performed as described previously.22 In brief, hearts were 
removed, washed in cold PBS and patted dry with sterile gauze prior to weighing. Mid-
ventricular slices were fixed in 4% paraformaldehyde and stored at 4°C for histological 
analyses. The remaining ventricular tissue was snap-frozen in liquid N2 and stored at -80°C 
for biochemical analyses. The lungs, liver, spleen and left kidney were weighed following 
removal (wet weight) and after dehydration at 50°C overnight (dry weight) for assessment of 
tissue congestion.  
Protein phosphatase assay 
Protein phosphatase activity was determined with [32P]-phosphorylase a as substrate and 3 
nmol/L okadaic acid was used to differentiate between PP1 and PP2A activity, as described 
previously.19, 20 
 
Histology 
LV collagen content (fibrosis) and myocyte cross-sectional area were quantified from 
transverse sections of the left ventricle, as described previously.23 In brief, mid-ventricular 
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tissue slices fixed in 4% paraformaldehyde and embedded in paraffin were sectioned (5 µm) 
and stained with picrosirius red or haematoxylin and eosin (H&E). Quantification of LV 
collagen content (from picrosirius red-stained sections) and myocyte cross-sectional area 
(from H&E-stained sections) was performed using Image Pro Plus 7.0 and Image J software, 
respectively.  
SDS-PAGE and immunoblotting  
Pulverised LV tissue was homogenised on ice in PBS supplemented with EDTA-free 
protease inhibitor (Roche 11873580001) and phosphatase inhibitor cocktail 3 (Sigma P0044) 
and lysed in sample buffer at 95°C for 10 minutes. Proteins were resolved on Tris-glycine 
SDS-PAGE gels and transferred to PVDF membranes. Phosphate affinity (PhosTag) SDS-
PAGE was performed on Tris-glycine gels containing acrylamide-pendant PhosTag and 
MnCl2, as previously described.18, 24, 25 Immunoblot analyses were performed using the 
following antibodies: PP2ACα (1:1000, Proteintech 13482-1-AP), PP2ACα/β (1:2000, Cell 
Signaling 2038), PP2AA (1:1000, Santa Cruz sc-74580) B56α (1:500, BD Transduction 
610615), B56γ (1:500, Abcam ab94633), B56δ (1:1000, Bethyl A301-100A), B55α (1:500, 
Santa Cruz sc-81606), α4 (1:2000, Bethyl A300-471A), phospho-PKA substrate RRXS/T 
(1:2000, Cell Signaling 9624), cTnI (1:2000, Cell Signaling 2002), pS16 PLB (1:4000, 
Badrilla A010-12AP), PLB (1:1000, Cell Signaling 8495), pS282 cMyBP-C (Enzo Life 
Sciences ALX-215-057-R050), RyR2 (1:500, Thermo Fisher Scientific MA3-925), α-actinin 
(1:10000, Abcam ab50599), GAPDH (1:1000, Cell Signaling 2118). The cMyBP-C and 
pS302 cMyBP-C antibodies were kind gifts from Mathias Gautel26 and Jeffrey Robbins,27 
and were used at 1:30,000 and 1:5000 respectively. The pS2808 and pS2814 RyR2 antibodies 
were kind gifts from Xander Wehrens28 and were used at 1:1000. The following HRP-linked 
secondary antibodies were used: anti-rabbit IgG (1:2500, Cell Signaling 7074), anti-rat IgG 
(1:2500, Cell Signaling 7077), anti-mouse IgG (1:2500, Dako P0447). Protein bands were 
visualised on chemiluminescence film, following the use of ECL Western Blotting Detection 
Reagents (GE Healthcare). Signals were quantified using Image J software (NIH; phospho-
PKA substrate blots) or on a calibrated GS-800 densitometer (Bio-Rad; all other blots). 
Cardiac PP2A subunit expression was normalised to α-actinin. Ventricular tissue treated with 
λ-phosphatase29 was included on PhosTag SDS-PAGE gels to confirm the specificity of the 
bands corresponding to mono- and bis-phosphorylated cTnI. 
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RT-qPCR 
LV tissue was homogenised, lysed and RNA isolated via phenol extraction. cDNA obtained 
from 1 µg RNA was diluted 5-fold for quantitative SYBR Green PCR analysis and 10-fold 
for TaqMan PCR analysis. Samples were run in triplicate, and mRNA expression normalised 
to Gapdh. Relative gene expression was calculated using the comparative ∆∆CT method. 
Results are presented as fold-change vs WT or WT Vehicle as appropriate. TaqMan 
probe/primer sets were from Applied Biosystems: Nppb: Mm01255770_g1; Gapdh: 
Mm99999915_g1. The following primers were used for SYBR Green PCR analysis: Myh6: 
for AACTACCACATCTTCTACC, rev TAGTCGTATGGGTTGTTG; Myh7: for 
GCTGTTATTGCCGCCATTG, rev GTTGTCATTCCGAACTGTCTTG; Nppa: for 
GGCTCCTTCTCCATCACC, rev CGGCATCTTCTCCTCCAG; Col1a1: for 
GCTCCTCTTAGGGGCCACT, rev CCACGTCTCACCATTGGGG; Col3a1: for 
CTGTAACATGGAAACTGGGGAAA, rev CCATAGCTGAACTGAAAACCACC; Gapdh: 
for AGGTCGGTGTGAACGGATTTG, rev GGGGTCGTTGATGGCAACA.  
Statistical analyses 
Quantitative data are presented as mean ± SE. Differences between groups were determined 
by unpaired t-test, or by one- or two-way ANOVA with Tukey’s post-hoc test, as appropriate. 
A P value less than 0.05 was considered significant. All statistical analyses were performed 
with Microsoft Excel 2007 and Graph Pad Prism 6.0 software. 
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RESULTS 
To explore the in vivo roles of B56α in regulating cardiac structure and function, we utilised a 
mouse line with targeted disruption of Ppp2r5a, the gene encoding B56α. This was achieved 
through a gene trap approach, with the trapping cassette inserted in intron 1 (Figure 1A). As 
illustrated in Figure 1B, relative to wild type (WT) mice, targeted disruption of Ppp2r5a gave 
rise to a partial loss of cardiac B56α protein in mice heterozygous for the mutant allele (HET) 
and complete loss of cardiac B56α protein in mice homozygous for the mutant allele (HOM). 
Interestingly, relative to WT mice, cardiac PP2A activity was found to be significantly 
reduced in both HET and HOM mice, with a somewhat greater reduction in the latter (Figure 
1C). 
To explore if the loss of B56α protein was associated with altered expression of other 
components of the heterotrimeric PP2A holoenzyme, we explored the protein levels of PP2A 
catalytic (PP2AC) and scaffolding (PP2AA) subunits, and three other PP2A regulatory B 
subunit isoforms (B56d, B56g and B55α), in hearts from WT, HET and HOM mice (Figure 
2). In the same samples, the expression of α4, an evolutionarily conserved PP2AC-binding 
protein,30 was also determined (Figure 2). Cardiac expression of PP2AC (determined using 
antibodies that recognise only the α isoform or both the α and β isoforms) and PP2AA 
(determined using an antibody that recognises both the α and β isoforms) was comparable in 
WT, HET and HOM mice. There was also no significant difference between genotypes in the 
cardiac expression of B56γ, B56δ or B55α, although a trend towards reciprocal changes in 
the expression of B56γ (decreased) and B56δ (increased) with increasing number of mutant 
Ppp2r5a alleles was observed (Figure 2). Interestingly, there was also a strong trend towards 
increased abundance of α4 occurring in parallel with the decreased abundance of B56α in 
HET and HOM mice (Figure 2).  
We also determined the phosphorylation profile of a number of phosphoproteins in hearts 
from WT and HOM mice. The use of a phosphospecific antibody that detects phosphorylated 
Ser/Thr residues within the optimal protein kinase A substrate motif (RRXS/T) allowed the 
detection of 12 discrete bands, which are likely to represent abundantly expressed 
phosphoproteins that possess one or more such residue(s) (Figure 3A). However, there 
appeared to be no striking difference between hearts from WT and HOM mice in the intensity 
of the signals from individual bands or the overall phosphorylation signal (Figure 3A). We 
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also explored the site-specific phosphorylation of two functionally important myofilament 
phosphoproteins, cTnI and cMyBP-C, and two phosphoproteins that regulate Ca2+ uptake into 
and release from the sarcoplasmic reticulum, PLB and RyR2. This analysis revealed no 
significant difference between hearts from WT and HOM mice in the phosphorylation status 
of the majority of the pertinent proteins and residues (Figure 3B-D). A notable exception was 
Ser2814 in RyR2, which exhibited significantly lower phosphorylation in hearts of HOM 
mice (Figure 3E). 
Complementary analyses of protein phosphorylation were performed in ventricular myocytes 
isolated from the hearts of adult WT and HOM mice and subjected to stimulation with 
vehicle or isoproterenol (ISO) in vitro. Consistent with our observations in mouse hearts, loss 
of B56α had no significant effect on the phosphorylation of cTnI, cMyBP-C or PLB in 
vehicle-treated cells (Supplementary Figure 1A-C). The phosphorylation of RyR2 tended to 
be lower in myocytes from HOM mice and was not altered by ISO stimulation in either 
genotype (Supplementary Figure 1D). ISO stimulation increased the abundance of mono- and 
bis-phosphorylated cTnI while reducing the abundance of non-phosphorylated cTnI, and 
increased the phosphorylation of cMyBP-C at Ser282 and Ser302 and PLB at Ser16, in 
myocytes from both WT and HOM mice (Supplementary Figure 1A-C).   
Basal cardiac structure and function in vivo were assessed by echocardiographic analysis in 
anesthetised mice at 2 months of age. This revealed no significant difference between 
genotypes in LV wall thicknesses, LV cavity size, LV contractile function or heart rate, in 
either sex (Figure 4A and Supplementary Tables 1-2). Gravimetric analyses also did not 
reveal any significant variation between genotypes in body or organ weight, in either sex 
(Figure 4B and Supplementary Tables 3-4). At 6 months of age, male HOM mice displayed a 
small, but significant, decrease in heart weight (HW) normalised to tibia length (TL; ~12% 
decrease vs WT; Supplementary Table 5). This was accompanied by a comparable decrease 
in lung weight (LW) normalised to TL (Supplementary Table 5). By echocardiography, 
interventricular septum (IVS) thickness was also reduced in the HOM mice (Supplementary 
Table 6), consistent with the decrease in HW/TL ratio. These differences were not apparent 
in 6-month old female mice (Supplementary Tables 7-8).  
Based on our previous work indicating that, in isolated adult rat ventricular cardiomyocytes, 
β-AR stimulation induces B56α translocation,17 we explored the impact of the loss of B56α 
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protein on cardiac responses to acute b-AR stimulation in vivo, again by echocardiographic 
analysis. This revealed that acute b-AR stimulation with dobutamine induced the predicted 
positive inotropic and positive chronotropic responses in WT and HET mice (Figure 5 and 
Supplementary Table 9). Interestingly, however, the positive inotropic response was 
attenuated while the positive chronotropic response was retained in HOM mice (Figure 5 and 
Supplementary Table 9). 
The differential cardiac inotropic response to acute b-AR stimulation in HOM mice prompted 
us to also investigate whether cardiac structural and functional responses to sustained b-AR 
stimulation are altered in this genotype. To that end, WT and HOM mice received 
subcutaneous infusion of saline (Control) or isoproterenol (ISO), delivered through implanted 
osmotic mini-pumps, for a 2-week period. As shown in Figure 6, in WT mice, ISO infusion 
induced significant thickening of the LV anterior and posterior walls at end-diastole, without 
a significant change in LV chamber size, which is indicative of LV hypertrophy without LV 
dilation. In HOM mice, the ISO-induced increases in LV wall thickness were much less 
marked and did not reach statistical significance relative to genotype-matched control mice 
receiving saline (Figure 6), suggesting attenuated LV hypertrophy. Similar to our 
observations with acute β-AR stimulation using dobutamine (Figure 5), there was a 
significant positive chronotropic response to ISO in both WT and HOM mice (Figure 6). 
There were no significant differences between groups in other echocardiographic parameters 
(Figure 6 and Supplementary Table 10). 
We also investigated ISO-induced LV remodelling in WT versus HOM mice by histological 
and gravimetric analyses. ISO infusion for 2 weeks led to a significant increase in LV 
myocyte cross-sectional area in WT mice, but not in HOM mice (Figure 7A). There was little 
detectable LV collagen in WT or HOM mice, as measured by picrosirius red staining, in the 
absence or presence of ISO infusion (Figure 7B). Ventricular weight (VW), in absolute terms 
or when normalised to TL, was significantly increased by ISO in WT mice, but not in HOM 
mice (Figure 7C). Gravimetric analyses of other organs did not reveal major differences 
between genotypes, except that ISO infusion induced a significant increase in lung weight in 
HOM but not WT mice (Supplementary Table 11). 
Gene expression analyses revealed that there was no significant difference between groups in 
the expression of Col1a1 or Col3a1, assessed as molecular markers of the induction of 
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cardiac fibrosis (Figure 7D). Similarly, there was no significant difference between groups in 
molecular markers of the induction of pathological cardiac hypertrophy, such as reciprocal 
changes in the expression of the myosin heavy chain genes Myh6 and Myh7 (Figure 7E) or 
increased expression of the natriuretic peptide genes Nppa and Nppb (Figure 7F).  
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DISCUSSION 
Our study provides an extensive characterisation of the impact of disrupting B56α expression 
on cardiac phenotype in mice, with focus on contractile and remodelling responses to acute 
and sustained b-AR stimulation, respectively. Our data indicate that loss of B56α does not 
influence resting cardiac structure and function, but it attenuates the cardiac inotropic 
response to acute b-AR stimulation and blunts the cardiac hypertrophy that arises from 
sustained b-AR stimulation. These observations build on our previous work that revealed 
translocation of B56α between subcellular compartments upon b-AR stimulation in 
cardiomyocytes17, 18 and suggest that B56α plays an important role in regulating cardiac 
responses to such stimulation in vivo. 
The role of B56α in regulating the inotropic response to acute b-AR stimulation was revealed 
by our observation of attenuated dobutamine-induced increases in LVFS and LVEF in HOM 
mice relative to their WT littermates (Figure 5). Interestingly, heart rate was increased 
significantly and to a similar extent in both WT and HOM mice in response to dobutamine, 
indicating that proximal b-AR signalling events, such as activation of adenylate cyclase by 
stimulatory G proteins, elevation of intracellular cAMP, and activation of cAMP-dependent 
protein kinase (PKA), are unaffected by the loss of B56α, at least in sinoatrial node 
pacemaker cells. An attenuated inotropic response to acute b-AR stimulation may arise from 
altered phosphorylation of myofilament or Ca2+-regulatory protein(s) in cardiomyocytes.4 Of 
note, we found no difference between hearts from WT and HOM mice in the phosphorylation 
status of cTnI, cMyBP-C or PLB (Figure 3B-D), suggesting that these phosphoproteins are 
not regulated by B56α-PP2A. Interestingly, RyR2 phosphorylation was unaffected at Ser2808 
(a PKA target residing in a TRRISQTSQ motif) but was significantly reduced at Ser2814 (a 
Ca2+/calmodulin-dependent kinase II (CaMKII) target residing in a TSQVSIDAA motif) in 
hearts from HOM mice relative those from WT mice (Figure 3E). It is important to note that, 
although these protein phosphorylation analyses were performed using hearts from mice that 
did not receive treatment with an exogenous b-AR agonist, euthanasia in mice is associated 
with marked sympathetic activation, as reflected by the ability of b-AR antagonists to 
markedly attenuate the phosphorylation of both cTnI and cMyBP-C when administered in 
vivo prior to euthanasia.31 Indeed, our observation of marked cTnI phosphorylation in WT 
hearts, in which approximately 50% of cTnI existed in the bis-phosphorylated (2P) state 
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(Figure 3B), attests to significant sympathetic activation prior to heart excision. Taken 
together, our findings suggest that, while altered cTnI, cMyBP-C or PLB phosphorylation is 
unlikely to play a role, reduced RyR2 phosphorylation at Ser2814 may contribute to the 
attenuated inotropic response to acute b-AR stimulation that we have observed in HOM 
mice. Nevertheless, this requires confirmation by further investigation, particularly in view of 
reservations regarding the importance of RyR2 phosphorylation at Ser2808 in mediating the 
positive inotropic effects of b-AR stimulation,32-34 and our observation that in ventricular 
myocytes isolated from either WT or HOM mice acute b-AR stimulation with ISO did not 
induce a significant change in RyR2 phosphorylation (Supplementary Figure 1). 
 
With regard to the pertinent molecular signalling mechanism, overexpression of the 
microRNA miR-1 in adult rat ventricular myocytes has been shown both to reduce B56α 
expression and to increase RyR2 phosphorylation at Ser2814, leading to the suggestion that 
RyR2 may be dephosphorylated at this site by B56α-PP2A.35 However, our current data and 
recent evidence from a similar model36 show that loss of B56α protein is associated with 
reduced, rather than increased, RyR2 phosphorylation at S2814 in mouse hearts, suggesting 
that this site is not a direct target for B56α-PP2A in vivo. It is likely, therefore, that any 
B56α-PP2A-mediated regulation of RyR2 phosphorylation occurs through an indirect 
mechanism, potentially through a downstream change in PP1 activity.37 
The blunted hypertrophic response to sustained b-AR stimulation in mice lacking B56α 
might arise, at least in part, from a diminished increase in cardiac workload, due to the 
attenuated inotropic response to such stimulation. Nevertheless, during sustained b-AR 
stimulation other pathways are also activated, including for example CaMKII and its 
downstream signalling mechanisms that precipitate pathological remodelling.38, 39 Whether 
B56α-PP2A is required for such signalling is currently unknown. It is worth noting, however, 
that the ISO-induced hypertrophy that we have observed in both WT and HOM mice was 
mild, with no indication of pathological remodelling as characterised by ventricular dilation 
(there was no significant increase in LVID at diastole or systole), increased interstitial 
fibrosis (there was no significant increase in Col1a1 or Col3a1 gene expression or LV 
collagen content), reduced LV function (there was no significant reduction in LVFS or 
LVEF) and upregulation of foetal genes (there was no significant change in myosin heavy 
chain or natriuretic peptide gene expression). The impact of B56α deletion on cardiac 
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phenotype following a more severe or prolonged stress stimulus remains to be determined. In 
this context, B56α expression has been reported to be significantly reduced in left ventricular 
myocardium of failing human hearts,20 although whether this is a causal or compensatory 
change is unknown. It is also worth noting that knock-in mice that express a mutated RyR2 
protein that cannot be phosphorylated at Ser2814 (Ser2814Ala) appear resistant to 
pathological cardiac remodelling that is induced by transverse aortic constriction40 or a 4-
week infusion of ISO.38  
In our studies, reduced cardiac B56α expression in HET and HOM mice was associated with 
reduced cardiac PP2A catalytic activity. A parallel reduction in cardiac B56α expression and 
PP2A catalytic activity has been reported previously in a mouse model of endotoxemia.41 
Furthermore, a 2-fold increase in cardiac B56α expression in transgenic mice was found to be 
associated with a parallel increase in PP2A catalytic activity.19 Taken together with our data, 
these studies suggest that in mouse myocardium B56α abundance is an important determinant 
of PP2A catalytic activity, most likely in specific subcellular compartments where the B56α-
PP2A holoenzyme is localised. Nevertheless, Little et al. have reported increased PP2A 
activity in mouse hearts with reduced B56α expression, using a similar model with targeted 
Ppp2r5a disruption.36 The reason for these discrepant findings is unclear. However, it is 
worth noting that while the three studies reporting a reduced PP2A activity (Marshall et al.,41 
Kirchhefer et al.19 and our present study) used protein or peptide substrates with 
phosphorylated Ser/Thr residues in their enzymatic assays, the study showing an increased 
PP2A activity36 used p-nitrophenyl phosphate, which is a chromogenic substrate targeted by 
various phosphatases, including protein tyrosine phosphatases and alkaline phosphatases.  
The reduction in PP2A catalytic activity that we have observed occurred in the absence of a 
change in the expression of C subunits, which was determined using antibodies recognising 
either the α isoform alone or both the α and β isoforms. This points towards a post-
translational mechanism for the observed reduction in cardiac PP2A activity in our mouse 
model. It is well established that B56α is abundantly expressed in the heart,16, 42 such that a 
partial or complete loss of B56α in HET and HOM hearts, respectively, might “release” a 
significant amount of C subunit that, unless sequestered by other regulatory proteins, could 
lead to uncontrolled PP2A activity. An important C subunit interacting protein that is distinct 
from B type regulatory subunits is α4, which is expressed in mouse myocardium43 and has 
been suggested to act as a binding partner for monomeric PP2A C subunits that prevents their 
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unregulated catalytic activity.30, 44 Interestingly, we have found that the graded reductions in 
B56α expression and PP2A catalytic activity in WT, HET and HOM hearts (Figure 1) were 
accompanied by a strong trend towards a reciprocal increase in α4 abundance (Figure 2). It is 
possible, therefore, that increased sequestration of PP2A C subunits by α4 contributed, at 
least in part, to the reduced PP2A catalytic activity that we have observed in HET and HOM 
hearts.  
In conclusion, our study has revealed that B56α modulates the cardiac inotropic response to 
acute b-AR stimulation and the cardiac hypertrophy response to sustained b-AR stimulation 
in the in vivo setting. Taken together with previous evidence that: (1) B56α translocates 
between subcellular compartments upon b-AR stimulation in cardiomyocytes;17, 18 (2) 
overexpression19 or disruption36 of B56α expression in mice has a marked impact on cardiac 
phenotype; and (3) there is a marked reduction in B56α expression in failing human hearts,20 
these findings indicate that B56α-PP2A may be a novel regulator of cardiac structure and 
function. Delineating the molecular mechanism(s) through which B56α-PP2A regulates 
cardiac structure and function, particularly in response to b-AR stimulation, requires further 
investigation, including the identification of putative B56α-PP2A substrates through broad 
spectrum phosphoproteomic analysis. 
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FIGURE LEGENDS 
Figure 1: Generation and characterisation of mice deficient for B56α. (A) Schematic of 
the gene encoding B56α (Ppp2r5a; exons in black) showing the insertion site of the gene trap 
cassette (BGEO) and locations of forward (F1, F2) and reverse (R) primers used to amplify 
regions of the wildtype and mutant alleles by PCR from genomic DNA of wildtype (WT), 
heterozygous (HET) and homozygous (HOM) mice. A DNA gel illustrating the outcome of a 
typical genotyping run is also shown. (B) Protein levels of B56α in ventricular tissue from 
WT, HET and HOM mice, assessed by immunoblotting (n=6 per group). (C) PP2A catalytic 
activity in ventricular tissue from WT, HET and HOM mice, assessed by a quantitative assay 
that uses 32P-labelled phosphorylase a as substrate (n=6-8 per group). Lines show mean ± SE; 
*P<0.05 (one-way ANOVA with Tukey’s post-hoc test).  
Figure 2: Cardiac expression of PP2A catalytic, scaffolding and regulatory subunits. 
Protein levels of PP2AC α isoform, PP2AC α and β isoforms, PP2AA α and β isoforms, B55α, 
B56γ, B56δ, and α4 in ventricular tissue from WT, HET and HOM mice, assessed by 
immunoblotting. Lines show mean ± SE (n=5-6 per group). There were no significant 
differences between groups (one-way ANOVA). 
Figure 3: Cardiac protein phosphorylation in wildtype and B56α-deficient mice. (A) 
Phosphorylation of Ser/Thr residues within the optimal protein kinase A substrate motif, 
assessed by immunoblotting with a pS/T (RRXS/T) antibody. Discrete bands on the 
immunoblot are numbered. Plots generated using a gel analysis tool (Image J software, NIH) 
show the peaks corresponding to each band in the WT and HOM samples marked with an 
asterisk (*). The overall phosphorylation signal for large (>37 kDa, upper blot) and small 
(<37 kDa, lower blot) proteins was quantified by measuring the area under the curve for each 
plot and normalising to α-actinin. Lines show mean ± SE (n=6 per group). There were no 
significant differences between genotypes (unpaired t-tests). (B) Abundance of non-
phosphorylated (0P), mono-phosphorylated (1P) and bis-phosphorylated (2P) cardiac 
troponin I (cTnI), as assessed by phosphate affinity (PhosTag) SDS-PAGE and 
immunoblotting. 0P, 1P and 2P phospho-moieties are expressed as a percentage of total cTnI, 
which is the sum of the signals in each lane. The specificity of the bands was confirmed by 
incubating with λ-phosphatase (λ-PP) to dephosphorylate cTnI. Lines show mean ± SE (n=6 
per group); *P<0.05 (two-way ANOVA with Tukey’s post-hoc test). (C) Phosphorylation of 
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cardiac myosin binding protein C (cMyBP-C) at Ser282, as assessed by immunoblotting. 
Lines show mean ± SE (n=6 per group). There was no significant difference between the 
genotypes (unpaired t-test). (D) Phosphorylation of phospholamban (PLB) at Ser16, as 
assessed by immunoblotting. Lines show mean ± SE (n=6 per group). There was no 
significant difference between genotypes (unpaired t-test). (E) Phosphorylation of ryanodine 
receptor 2 (RyR2) at Ser2808 and Ser2814, as assessed by immunoblotting. Lines show mean 
± SE (n=6 per group); *P<0.05 (unpaired t-test).  
 
Figure 4: Echocardiographic and gravimetric analysis of basal cardiac phenotype. (A) 
Echocardiographic assessment of left ventricular (LV) anterior wall thickness at end-systole 
(LVAWs), LV internal dimension at end-systole (LVIDs), LV fractional shortening (FS), LV 
ejection fraction (EF) and heart rate (HR) in male WT, HET and HOM mice at 8 weeks of 
age. Lines are mean ± SE (n=20-28 per group). There were no significant differences 
between groups (one-way ANOVA). (B) Heart weight (HW), body weight (BW), HW 
normalised to BW and tibia length (TL), and lung weight of male WT, HET and HOM mice 
at 8 weeks of age. Lines show mean ± SE (n=6-11 per group for all parameters except lung 
weight, for which n=6 per group). There were no significant differences between groups 
(one-way ANOVA). 
Figure 5: Echocardiographic analysis of cardiac responses to acute β-adrenergic 
stimulation. Echocardiographic assessment of (A) left ventricular (LV) anterior wall 
thickness at end-systole (LVAWs), (B) LV posterior wall thickness at end-systole (LVPWs), 
(C) LV internal dimension at end-systole (LVIDs), (D) LV fractional shortening (FS), (E) LV 
ejection fraction (EF) and (F) heart rate (HR) in male WT, HET and HOM mice following 
intraperitoneal injection of dobutamine (DOB, 0.75 mg/kg) or vehicle. Lines show mean ± 
SE (n=8-10 per group); * P<0.05 (two-way ANOVA with Tukey’s post-hoc test). 
Figure 6: Echocardiographic analysis of cardiac responses to sustained β-adrenergic 
stimulation. Echocardiographic assessment of (A) left ventricular (LV) anterior wall 
thickness (LVAW), (B) LV posterior wall thickness (LVPW) and (C) LV internal dimension 
(LVID) at end-diastole (d) and end-systole (s), and (D) LV fractional shortening (LVFS), (E) 
LV ejection fraction (LVEF) and (F) heart rate in male WT and HOM mice following 
subcutaneous infusion of isoproterenol (ISO; 30 mg/kg/day) or vehicle for 14 days. Lines 
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show mean ± SE (n=6-8 per group); * P<0.05 (two-way ANOVA with Tukey’s post-hoc 
test). 
Figure 7: Histological, gravimetric and molecular analysis of cardiac responses to 
sustained β-adrenergic stimulation. (A) Cross-sections of the left ventricle (LV) stained 
with haematoxylin and eosin to allow quantification of myocyte cross-sectional area. 
Representative images (magnification ×400) and quantitative data from male WT and HOM 
mice following subcutaneous infusion of isoproterenol (ISO; 30 mg/kg/day) or vehicle for 14 
days. Scale bar: 20 µm. Lines show mean ± SE (>50 myocytes were measured from 5-8 
hearts per group); * P<0.05 (two-way ANOVA with Tukey’s post-hoc test). (B) Cross-
sections of the LV stained with picrosirius red to allow quantification of LV collagen content. 
Representative images (magnification ×100) and quantitative data from male WT and HOM 
mice following subcutaneous infusion of isoproterenol (ISO; 30 mg/kg/day) or vehicle for 14 
days. Scale bar: 80 µm. Lines show mean ± SE (n=5-7 per group). There were no significant 
differences between groups (two-way ANOVA). (C) Ventricular weight (VW) and VW 
normalised to tibia length (TL) of male WT and HOM mice following subcutaneous infusion 
of isoproterenol (ISO; 30 mg/kg/day) or vehicle for 14 days. Lines show mean ± SE (n=5-10 
per group); * P<0.05 (two-way ANOVA with Tukey’s post-hoc test). (D-F) RT-qPCR 
analysis of Col1a1, Col3a1, Myh6, Myh7, Nppa and Nppb mRNA transcript levels in hearts 
from male WT and HOM mice following subcutaneous infusion of isoproterenol (ISO; 30 
mg/kg/day) or vehicle for 14 days. Lines show mean ± SE (n=5-8 per group). There were no 
significant differences between groups (two-way ANOVA). 
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